Therapy Areas: Oncology
OncoZenge secures European approval for Phase III BEAM-Pain trial of BupiZenge
26 May 2026 - Swedish pharmaceutical company OncoZenge AB (Nasdaq First North Growth Market:ONCOZ) announced on Tuesday that it has received European regulatory approval to initiate its pivotal Phase ...
Transgene to present preclinical TG-MVA mpox vaccine data at World Congress on Infectious Diseases
26 May 2026 - French biotech company Transgene (Euronext Paris:TNG) announced on Tuesday that it will present new preclinical data on its TG-MVA prophylactic vaccine candidates against mpox at the Wor...
Pierre Fabre Laboratories' BRAFTOVI (encorafenib) combination receives CHMP positive opinion in BRAFV600E-mutant mCRC
26 May 2026 - French pharmaceutical company Pierre Fabre Laboratories announced on Monday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issu...
Menarini Group to present new elacestrant and tagraxofusp data at ASCO 2026 Annual Meeting
26 May 2026 - Italian pharmaceutical and diagnostics company the Menarini Group and its subsidiary Stemline Therapeutics Inc announced on Monday that new data related to elacestrant and tagraxofusp wi...
Enhertu recommended for EU approval in previously treated HER2 positive metastatic solid tumours
22 May 2026 - Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) announced on Friday that Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union as a monoth...
OSE Immunotherapeutics reports positive Phase 2 ovarian cancer trial results
22 May 2026 - French biotechnology company OSE Immunotherapeutics SA (Euronext Paris:OSE) on Friday reported positive topline results from the Phase 2 TEDOVA trial evaluating Tedopi, with or without p...